5:58 PM
 | 
Mar 03, 2014
 |  BC Extra  |  Clinical News

Roche discontinues NSCLC trial of onartuzumab

Roche (SIX:ROG; OTCQX:RHHBY) discontinued the Phase III METLung trial evaluating IV MetMAb onartuzumab plus Tarceva erlotinib as a second- or third-line treatment for metastatic non-small cell lung cancer (NSCLC) patients with MET-positive tumors. The move came after top-line data from...

Read the full 194 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >